FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Quarterly Report Under Section 13 or 15(d)
of the Securities Exchange Act of 1934
For Quarter Ended: December 31, 2001
Commission file number: 0-11363
CHAD THERAPEUTICS, INC.
| California | 95-3792700 | |
| (State of other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
| 21622 Plummer Street, Chatsworth, CA 91311 | ||
| (Address of principal executive offices) | (Zip Code) | |
(818) 882-0883
(Former name, former address and former fiscal year, if changed since last report.)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X... No....
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
Common Shares |
10,053,000 |
| Condensed Balance Sheets | ||||||||
| Condensed Statements of Operations | ||||||||
| Condensed Statements of Operations | ||||||||
| Condensed Statement of Shareholders’ Equity | ||||||||
| Condensed Statements of Cash Flows | ||||||||
| SIGNATURES | ||||||||
CHAD THERAPEUTICS, INC.
Condensed Balance Sheets
December 31, 2001 and March 31, 2001
(Unaudited)
ASSETS
| December 31, | March 31, | ||||||||||
| 2001 | 2001 | ||||||||||
Current Assets: |
|||||||||||
Cash |
$ | 570,000 | $ | 1,059,000 | |||||||
Accounts receivable, less allowance for
doubtful accounts of $69,000 at
December 31, 2001 and $33,000 at
March 31, 2001 |
3,078,000 | 2,352,000 | |||||||||
Inventories (Note 2) |
4,568,000 | 3,415,000 | |||||||||
Prepaid expenses |
411,000 | 598,000 | |||||||||
Total current assets |
8,627,000 | 7,424,000 | |||||||||
Property and equipment, at cost |
5,886,000 | 5,576,000 | |||||||||
Less accumulated depreciation |
4,154,000 | 3,534,000 | |||||||||
Net property and equipment |
1,732,000 | 2,042,000 | |||||||||
Other assets, net |
1,237,000 | 1,322,000 | |||||||||
Total assets |
$ | 11,596,000 | $ | 10,788,000 | |||||||
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|||||||||||
Current liabilities: |
|||||||||||
Accounts payable |
$ | 1,143,000 | $ | 465,000 | |||||||
Accrued expenses |
1,078,000 | 1,109,000 | |||||||||
Income taxes payable |
3,000 | 3,000 | |||||||||
Total current liabilities |
2,224,000 | 1,577,000 | |||||||||
Shareholders’ equity: |
|||||||||||
Common shares, $.01 par value, authorized
40,000,000 shares; 10,053,000 and 10,052,000
shares issued and outstanding |
13,092,000 | 13,092,000 | |||||||||
Accumulated deficit |
(3,720,000 | ) | (3,881,000 | ) | |||||||
Total shareholders’ equity |
9,372,000 | 9,211,000 | |||||||||
Total liabilities and shareholders’ equity |
$ | 11,596,000 | $ | 10,788,000 | |||||||
See accompanying notes to condensed financial statements.
CHAD THERAPEUTICS, INC.
Condensed Statements of Operations
For the three months ended December 31, 2001 and 2000
(Unaudited)
| Three Months Ended | |||||||||||
| December 31, | |||||||||||
| 2001 | 2000 | ||||||||||
Net sales |
$ | 4,669,000 | $ | 2,757,000 | |||||||
Cost of sales |
2,817,000 | 2,208,000 | |||||||||
Gross profit |
1,852,000 | 549,000 | |||||||||
Costs and expenses: |
|||||||||||
Selling, general and administrative |
1,582,000 | 1,268,000 | |||||||||
Research and development |
200,000 | 165,000 | |||||||||
Total costs and expenses |
1,782,000 | 1,433,000 | |||||||||
Operating income (loss) |
70,000 | (884,000 | ) | ||||||||
Other income — interest income, net |
12,000 | 28,000 | |||||||||
Earnings (loss) before income taxes |
82,000 | (856,000 | ) | ||||||||
Income tax expense |
1,000 | — | |||||||||
Net earnings (loss) |
$ | 81,000 | $ | (856,000 | ) | ||||||
Basic earnings (loss) per share |
$ | .01 | $ | (.09 | ) | ||||||
Diluted earnings (loss) per share |
$ | .01 | $ | (.09 | ) | ||||||
Weighted average shares outstanding: |
|||||||||||
Basic |
10,053,000 | 10,044,000 | |||||||||
Diluted |
10,738,000 | 10,044,000 | |||||||||
See accompanying notes to condensed financial statements.
CHAD THERAPEUTICS, INC.
Condensed Statements of Operations
For the nine months ended December 31, 2001 and 2000
(Unaudited)
| Nine Months Ended | |||||||||||
| December 31, | |||||||||||
| 2001 | 2000 | ||||||||||
Net sales |
$ | 14,622,000 | $ | 8,856,000 | |||||||
Cost of sales |
9,172,000 | 6,881,000 | |||||||||
Gross profit |
5,450,000 | 1,975,000 | |||||||||
Costs and expenses: |
|||||||||||
Selling, general and administrative |
4,723,000 | 3,817,000 | |||||||||
Research and development |
605,000 | 486,000 | |||||||||
Total costs and expenses |
5,328,000 | 4,303,000 | |||||||||
Operating income (loss) |
122,000 | (2,328,000 | ) | ||||||||
Other income — interest income, net |
43,000 | 67,000 | |||||||||
Earnings (loss) before income taxes |
165,000 | (2,261,000 | ) | ||||||||
Income tax expense |
4,000 | — | |||||||||
Net earnings (loss) |
$ | 161,000 | $ | (2,261,000 | ) | ||||||
Basic earnings (loss) per share |
$ | .02 | $ | (.23 | ) | ||||||
Diluted earnings (loss) per share |
$ | .02 | $ | (.23 | ) | ||||||
Weighted average shares outstanding: |
|||||||||||
Basic |
10,053,000 | 10,041,000 | |||||||||
Diluted |
10,473,000 | 10,041,000 | |||||||||
See accompanying notes to condensed financial statements.
CHAD THERAPEUTICS, INC.
Condensed Statement of Shareholders’ Equity
For the nine months ended December 31, 2001
(Unaudited)
| Common Shares | ||||||||||||
| Accumulated | ||||||||||||
| Shares | Amount | Deficit | ||||||||||
Balance at
March 31, 2001 |
10,052,000 | $ | 13,092,000 | $ | (3,881,000 | ) | ||||||
Options Exercised |
1,000 | — | — | |||||||||
Net earnings |
— | — | 161,000 | |||||||||
Balance at
December 31, 2001 |
10,053,000 | $ | 13,092,000 | $ | (3,720,000 | ) | ||||||
See accompanying notes to condensed financial statements.
CHAD THERAPEUTICS, INC.
Condensed Statements of Cash Flows
For the nine months ended December 31, 2001 and 2000
(Unaudited)
| Nine Months Ended | ||||||||||||
| December 31, | ||||||||||||
| 2001 | 2000 | |||||||||||
Cash flows from operating activities: |
||||||||||||
Net earnings (loss) |
$ | 161,000 | $ | (2,261,000 | ) | |||||||
Adjustments to reconcile net earnings (loss) to
net cash provided by operating activities: |
||||||||||||
Depreciation and amortization of property and
equipment |
622,000 | 597,000 | ||||||||||
Amortization of intangibles |
86,000 | 71,000 | ||||||||||
Compensation expense related to stock issued |
— | 11,000 | ||||||||||
Changes in assets and liabilities: |
||||||||||||
Decrease (increase) in accounts receivable |
(726,000 | ) | (261,000 | ) | ||||||||
Decrease (increase) in inventories |
(1,153,000 | ) | 1,219,000 | |||||||||
Decrease (increase) in income taxes
refundable |
— | 175,000 | ||||||||||
Decrease (increase) in prepaid expenses |
187,000 | 188,000 | ||||||||||
Decrease (increase) in other assets |
(1,000 | ) | (54,000 | ) | ||||||||
Increase (decrease) in accounts payable |
678,000 | 87,000 | ||||||||||
Increase (decrease) in accrued expenses |
(31,000 | ) | (64,000 | ) | ||||||||
Increase (decrease) in income taxes payable |
— | — | ||||||||||
Net cash provided by (used in)
operating activities |
(177,000 | ) | (292,000 | ) | ||||||||
Cash flows from investing activities: |
||||||||||||
Capital expenditures |
(312,000 | ) | (125,000 | ) | ||||||||
Net cash used in investing
activities |
(312,000 | ) | (125,000 | ) | ||||||||
Net increase (decrease) in cash |
(489,000 | ) | (417,000 | ) | ||||||||
Cash beginning of period |
1,059,000 | 1,772,000 | ||||||||||
Cash end of period |
$ | 570,000 | $ | 1,355,000 | ||||||||
See accompanying notes to condensed financial statements.
CHAD THERAPEUTICS, INC.
December 31, 2001
(Unaudited)
| 1. | Interim Reporting |
| Chad Therapeutics, Inc. (the Company) is in the business of developing, producing and marketing respiratory care devices designed to improve the efficiency of oxygen delivery systems for home health care and hospital treatment of patients suffering from pulmonary diseases. |
| In the opinion of management, all adjustments necessary, which are of a normal and recurring nature, for a fair presentation of the results for the interim periods presented have been made. The results for the nine-month period ended December 31, 2001, are not necessarily indicative of the results expected for the year ended March 31, 2002. The interim statements are condensed and do not include some of the information necessary for a more complete understanding of the financial data. Accordingly, your attention is directed to the footnote disclosures found in the March 31, 2001, Annual Report and particularly to Note 1 which includes a summary of significant accounting policies. |
| 2. | Inventories |
| Inventories in 2001, are summarized as follows: |
| December 31, | March 31, | |||||||
Finished goods |
$ | 593,000 | 930,000 | |||||
Work-in-process |
1,229,000 | 594,000 | ||||||
Raw materials |
2,746,000 | 1,891,000 | ||||||
| $ | 4,568,000 | 3,415,000 | ||||||
| 3. | Earnings (Loss) Per Common Share |
| Following is a reconciliation of the numerators and denominators used in the calculation of basic and diluted earnings (loss) per common shares: |
| Three Months Ended | Nine Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2001 | 2000 | 2001 | 2000 | |||||||||||||
Basic earnings (loss) per share: |
||||||||||||||||
Numerator-net earnings (loss) |
$ | 81,000 | $ | (856,000 | ) | $ | 161,000 | $ | (2,261,000 | ) | ||||||
Denominator-weighted average
common shares outstanding |
10,053,000 | 10,044,000 | 10,053,000 | 10,041,000 | ||||||||||||
Basic earnings (loss) per share |
$ | .01 | $ | (.09 | ) | $ | .02 | $ | (.23 | ) | ||||||
CHAD THERAPEUTICS, INC.
December 31, 2001
(Unaudited)
| 3. | Earnings (Loss) Per Common Share (cont’d) |
Diluted earnings (loss) per share: |
||||||||||||||||
Numerator-net earnings (loss) |
$ | 81,000 | $ | (856,000 | ) | $ | 161,000 | $ | (2,261,000 | ) | ||||||
Denominator: |
||||||||||||||||
Weighted average common
shares outstanding |
10,053,000 | 10,044,000 | 10,053,000 | 10,041,000 | ||||||||||||
Dilutive effect of common
stock options |
685,000 | — | 420,000 | — | ||||||||||||
| 10,738,000 | 10,044,000 | 10,473,000 | 10,041,000 | |||||||||||||
Diluted earnings (loss) per share |
$ | .01 | $ | (.09 | ) | $ | .02 | $ | (.23 | ) | ||||||
| Options to purchase 447,000 shares of common stock at prices ranging from $3.14 to $13.47 per share and 1,178,000 shares of common stock at prices ranging from $.88 to $13.47 per share were not included in the computation of diluted earnings (loss) per share for the three and nine month periods ended December 31, 2001 and 2000, respectively, because their effect would have been anti-dilutive. |
| 4. | Income Taxes |
| Income taxes for the periods ended December 31, 2001, relate to minimum state income taxes due for the period. The Company has federal and California net operating loss carryforwards at December 31, 2001, of $3,856,000 and $2,928,000, respectively, against which a full valuation allowance has been recorded. |
| 5. | Geographic Information |
| The Company has one reportable operating segment. Geographic information regarding the Company’s sales is as follows: |
| Three Months Ended | Nine Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2001 | 2000 | 2001 | 2000 | |||||||||||||
United States |
$ | 4,446,000 | $ | 2,385,000 | $ | 13,575,000 | $ | 7,388,000 | ||||||||
Germany |
12,000 | 162,000 | 346,000 | 429,000 | ||||||||||||
Japan |
113,000 | 112,000 | 236,000 | 559,000 | ||||||||||||
All other countries |
98,000 | 98,000 | 465,000 | 480,000 | ||||||||||||
| $ | 4,669,000 | $ | 2,757,000 | $ | 14,622,000 | $ | 8,856,000 | |||||||||
| All long-lived assets are located in the United States. | |
| Sales of OXYMATIC® conservers and OXYLITE® systems accounted for 60% and 41% of the Company’s sales for the three and nine month periods ended December 31, 2001 and 2000, respectively. |
CHAD THERAPEUTICS, INC.
Management’s Discussion and Analysis of
Financial Condition and Results of Operations
December 31, 2001
Overview
The Company develops, assembles and markets medical devices that furnish supplementary oxygen to home health care patients. The Company was a pioneer in developing oxygen conserving devices that enhance the quality of life for patients by increasing their mobility and, at the same time, lower operating costs by achieving significant savings in the amount of oxygen actually required to properly oxygenate patients. The market for oxygen conserving devices has been significantly affected during the past several years by increased competition, consolidation among home oxygen dealers and revisions (and proposed revisions) in governmental reimbursement policies. All of these factors, as described more fully below, contributed to an erosion of the Company’s market share from 1998 through the fiscal year ended March 31, 2001, as devices that were less expensive but which provide lower oxygen savings (or, in some cases, do not truly provide ambulatory oxygen) prospered in this environment. The Company’s market share for conservers had also been affected by the introduction of competing devices that offered features not available on the OXYMATIC 301, which was the Company’s primary product in this market until July of 2000.
In 1998 the Company introduced the TOTAL O2 Delivery System, which combines the benefits of an oxygen concentrator with a system enabling patients to refill their portable cylinders. Initial sales of the TOTAL O2 system by home oxygen dealers were slowed by several factors discussed below.
In order to address this situation, the Company implemented a four-part strategy:
| • | Introduction of the OXYMATIC 400 series in July 2000 with improved features, which place these oxygen conservers at the forefront of the industry; | |
| • | Development of additional oxygen conserver models that will diversify the product line in order to offer customers a range of oxygen conservation choices; | |
| • | A continued promotional and educational campaign with respect to the benefits of the TOTAL O2 system, coupled with greater focus on monitoring the performance of component suppliers; and | |
| • | Cost cutting to align the Company’s operating expenses more closely with its revenue profile. |
While these measures have had a positive impact and management believes they should continue to enhance the Company’s competitive position and future operating performance, no assurances can be given that these objectives will be achieved. Management of the Company will continually monitor the success of these efforts and will attempt to remain flexible in order to adjust to possible future changes in the market for oxygen conserving devices.
CHAD THERAPEUTICS, INC.
Management’s Discussion and Analysis of
Financial Condition and Results of Operations
December 31, 2001
Results of Operations
Sales for the three months ended December 31, 2001 and 2000, increased $1,912,000 (69.4%) and decreased $202,000 (6.8%) and for the nine months ended December 31, 2001 and 2000, increased $5,766,000 (65.1%) and decreased $1,157,000 (11.6%), respectively, as compared to the prior year’s periods. The decrease in sales in 2000 related primarily to price reductions and lower domestic unit sales of OXYMATIC conservers and OXYLITE complete portable oxygen systems which were being affected by the marketing environment for home oxygen therapy discussed below. The increase in sales in 2001 is a result of sales of the new OXYMATIC 400 series conservers and sales of the TOTAL O2 system. Domestic unit sales of conservers for the nine months ended December 31, 2001 increased 199.3% as compared to a dollar increase of 137.7% due to price reductions and the effects of national chain contract pricing (see below).
Sales to foreign distributors represented 7% and 17% of total sales for the nine months ended December 31, 2001 and 2000, respectively. Currently, management expects an increase in sales to foreign distributors during the upcoming twelve months, however, quarter-to-quarter sales may fluctuate depending on the timing of shipments. All foreign sales are denominated in US dollars.
The current procedures for reimbursement by Medicare for home oxygen services provide a prospective flat fee monthly payment based solely on the patient’s prescribed oxygen requirement. Under this system, inexpensive concentrators have grown in popularity because of low cost and less frequent servicing requirements. At the same time, interest heightened in oxygen conserving devices, such as the Company’s products, which can extend the life of oxygen supplies and reduce service calls by dealers, thereby providing improved mobility for the patient and cost savings for dealers. In January of 1998 and 1999, the Federal government implemented reimbursement cuts of 25% and 5%, respectively. These cuts affected homecare providers’ purchasing patterns as they struggled to deal with significant reductions in their revenues.
In addition, other changes in the health care delivery system, including the increase in the acceptance and utilization of managed care, have stimulated a significant consolidation among home oxygen dealers. As major national and regional home medical equipment chains attempt to secure managed care contracts and improve their market position, they have expanded their distribution networks through the acquisition of independent dealers in strategic areas. Three major national chains accounted for approximately 34% and 16% of the Company’s domestic sales for the nine-month periods ended December 31, 2001 and 2000, respectively, with one chain accounting for 19% of sales for the nine months ended December 31, 2001. Margins on these sales are generally lower due to quantity pricing and consolidation has, in certain instances, resulted in reduced purchases as the former independent provider complies with the chain’s purchasing policies. To ensure continued awareness of the benefits of the Company’s products by chain
CHAD THERAPEUTICS, INC.
Management’s Discussion and Analysis of
Financial Condition and Results of Operations
December 31, 2001
Results of Operations (cont’d)
headquarters’ personnel, a proactive marketing and communication program is in effect with all of the major national chains. As stated above, the Company believes that its revenues during the three years ending March 31, 2001, were adversely affected by several factors. These include price competition, continuing industry consolidation and competitive products with features not found in the Company’s products prior to the introduction of the OM-400 series conservers discussed below. The effects of managed care and concerns over the severity of reimbursement cuts have, in many cases, resulted in the provision of systems to patients that do not provide truly ambulatory oxygen. Management believes these factors may continue to affect the Company’s revenues from sales of oxygen conserving devices for the foreseeable future. To combat the erosion in sales of the oxygen conserver product line, the Company is developing and introducing several new products in this area. The first of these, the OXYMATIC 401 conserver, received 501(k) clearance from the Food and Drug Administration in June 2000, and shipments of the new product began in July 2000. The second, the OXYMATIC 411 conserver was cleared in December 2000, and shipments began in January 2001. The third, the OXYMATIC 401A and 411A conservers, received clearance in March 2001 with shipments beginning that month. The most recent was the introduction of the Sequoia OXYMATIC 300 series conservers, which the Company began shipping in December 2001. Management believes the features and improvements in these products have enabled the Company to regain some of the market share lost in the conserver market over the prior three years. No estimate can currently be made regarding the level of success the Company may achieve with the OXYMATIC 400 series conservers. For information, which may affect the forward- looking statements made in this paragraph about the OXYMATIC 400 series conservers, see Outlook: Issues and Risks — New Products.
Management also believes that, based on its experience in the home oxygen industry, future revenues may be positively affected by sales of the TOTAL O2 Delivery System. The TOTAL O2 system provides stationary oxygen for patients at home, portable oxygen, including an oxygen conserving device for ambulation and a safe and efficient mechanism for filling portable oxygen cylinders. This should provide home care dealers with means to deal with the reimbursement cuts discussed above by reducing their monthly cost of servicing patients while at the same time providing a higher quality of service by maximizing ambulatory capability. The Company received clearance in November 1997, to sell this product from the Food and Drug Administration. Initial sales of the TOTAL O2 system were adversely affected by several factors, including the overall home oxygen market climate as well as start-up manufacturing and related supplier quality issues. The Company has taken a number of steps to resolve the manufacturing and supplier issues, however, the Company believes that further progress in this regard will be required before the TOTAL O2 system can realize its full market potential. In October 2001, a customer that was purchasing significant numbers of TOTAL O2 systems was acquired by a national chain that has discontinued those purchases. The Company
CHAD THERAPEUTICS, INC.
Management’s Discussion and Analysis of
Financial Condition and Results of Operations
December 31, 2001
Results of Operations (cont’d)
believes the sales potential for this system is significant as the market size for units is similar to the conserver market and the average selling price is approximately four times that of the OXYMATIC and OXYLITE systems. No estimates can currently be made regarding the level of success the Company may achieve with the TOTAL O2 system. For information which may affect the outcome of forward-looking statements made in this paragraph about the TOTAL O2 systems, see Outlook: Issues and Risks — New Products.
Cost of sales as a percent of net sales decreased from 80.1% to 60.3% and increased from 69.1% to 80.1% for the three month periods ended December 31, 2001 and 2000 and decreased from 77.7% to 62.7% and increased from 66.6% to 77.7% for the nine month periods ended December 31, 2001 and 2000, respectively, as compared to the prior year’s periods. The three and nine months ended December 31, 2001, were primarily affected by increased sales volume while the corresponding prior year’s periods were affected by decreased sales volume and the corresponding impact of fixed overhead costs on units produced, price competition and the lower gross profit margin on the TOTAL O2 system.
Selling, general and administrative expenditures increased from $1,268,000 (46% of sales) to $1,582,000 (34% of sales) and increased from $3,817,000 (43% of sales) to $4,723,000 (32% of sales) for the three and nine month periods ended December 31, 2001, respectively. The increase in 2001 is primarily the result of variable selling expenses that fluctuate directly with sales volume. The Company’s cost reduction efforts over the past two years, including reductions in personnel, should align staffing and operating expenses more closely with current sales expectations, but will be offset to some extent by commissions paid to the Company’s field sales force of manufacturer’s representatives. Research and development expenses increased by $35,000 and $119,000 for the three and nine month periods ended December 31, 2001, as compared to the prior year’s periods. Currently, management expects research and development expenditures to total approximately $830,000 in the fiscal year ended March 31, 2002, on projects to enhance and expand the Company’s product line. Interest income decreased $24,000 for the nine months ended December 31, 2001, as compared to the prior year’s period due to generally higher cash balances than in the prior year and lower interest rates in the current year.
At December 31, 2001, the Company had fully utilized its net operating loss carrybacks and had approximately $3,856,000 and $2,928,000 in Federal and California net operating loss carryforwards, respectively. As a result of valuation allowances placed on the net operating loss carryforwards and deferred tax assets, these net operating loss carryforwards and deferred tax assets will be available to offset future income tax expense when and if the Company generates taxable income.
CHAD THERAPEUTICS, INC.
Management’s Discussion and Analysis of
Financial Condition and Results of Operations
December 31, 2001
Financial Condition
At December 31, 2001, the Company had cash totaling $570,000 or 5% of total assets, as compared to $1,059,000 (10% of total assets) at March 31, 2001. Net working capital increased from $5,847,000 at March 31, 2001 to $6,403,000 at December 31, 2001. Accounts receivable increased $726,000 during the nine months ended December 31, 2001, due to the increase in sales. Future increases or decreases in accounts receivable will generally coincide with sales volume fluctuations and the timing of shipments to foreign customers. During the same period, inventories increased $1,153,000. This increase relates primarily to purchase of raw materials to keep up with increasing sales demand. The Company attempts to maintain sufficient inventories to meet its customer needs as orders are received. Thus, future inventory and related accounts payable levels will be impacted by the ability of the Company to maintain its safety stock levels. If safety stock levels drop below target amounts, then inventories in subsequent periods will increase more rapidly as inventory balances are replenished. Currently, inventory balances are generally near safety stock levels.
Management believes cash balances and funds derived from operations should be adequate to meet the Company’s cash requirements for the next twelve months given the recent recovery of market share for oxygen conservers. Cash derived from operations will depend on the ability of the Company to maintain profitable operations and the timing of increases in receivables and inventories. If operations do not continue to improve, the Company may need to seek other sources of working capital but currently has no such arrangements in place and no assurances can be given that if and when needed other sources of working capital would be available. The Company expects capital expenditures during the next twelve months to be approximately $200,000.
The Company has not adopted any programs that provide for post employment retirement benefits, however, it has on occasion provided such benefits to individual employees.
Outlook: Issues & Risks
This quarterly report contains forward-looking statements, which reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties, which may cause actual operating results to differ materially from currently, anticipated results. Among the factors that could cause actual results to differ materially are the following:
Dependence Upon a Single Product Line
Although the Company currently markets a number of products, these products comprise a single product line for patients requiring supplementary oxygen. The Company’s future performance is thus dependent upon developments affecting this segment of the health care market and the Company’s ability to remain competitive within this market sector.
CHAD THERAPEUTICS, INC.
Management’s Discussion and Analysis of
Financial Condition and Results of Operations
December 31, 2001
New Products
The Company’s future growth in the near term will depend in significant part upon the commercial success of the OXYMATIC 400 series conservers, the TOTAL O2 Delivery System and other new products which are under development. The success of these new products will depend upon the health care community’s perception of such products capabilities, clinical efficacy and benefit to patients and obtaining timely regulatory approval. In addition, prospective sales will be impacted by the degree of acceptance achieved among home oxygen dealers and patients requiring supplementary oxygen. As with the introduction of any new product, the Company’s ability to successfully promote the TOTAL O2 Delivery System, the OXYMATIC 400 series conservers and other new products cannot be assessed at this time.
Consolidation of Home Care Industry
The home health care industry is undergoing significant consolidation. As a result, the market for the Company’s products is increasingly influenced by major national chains. Three major national chains accounted for 34% of the Company’s domestic sales during the period ended December 31, 2001. Future sales may be increasingly dependent on a limited number of customers, which may have an impact on margins due to quantity pricing.
Competition
Chad’s success in the early 1990’s has drawn new competition to vie for a share of the home oxygen market. These new competitors include both small and very large companies. While the Company believes the quality of its products and its established reputation will continue to be a competitive advantage, some competitors have successfully introduced lower priced products with features not previously found in the Company’s products but which do not provide oxygen conserving capabilities comparable to the Company’s products. Most of these competitors have greater capital resources than the Company. No assurance can be given that increased competition in the home oxygen market will not continue to have an adverse affect on the Company’s operations.
Rapid Technological Change
The health care industry is characterized by rapid technological change. The Company’s products may become obsolete as a result of new developments. The Company’s ability to remain competitive will depend to a large extent upon its ability to anticipate and stay abreast of new technological developments related to oxygen therapy. The Company has limited internal research and development capabilities. Historically, the Company has
CHAD THERAPEUTICS, INC.
Management’s Discussion and Analysis of
Financial Condition and Results of Operations
December 31, 2001
Rapid Technological Change (cont’d)
contracted with outside parties to develop new products. Some of the Company’s competitors have substantially greater funds and facilities to pursue research and development of new products and technologies for oxygen therapy.
Potential Changes in Administration of Health Care
A number of bills proposing to regulate, control or alter the method of financing health care costs have been discussed and certain of such bills have been introduced in Congress and various state legislatures. Because of the uncertain state of health care proposals, it is not meaningful at this time to predict the effect on the Company if any of these proposals is enacted.
Approximately 80% of home oxygen patients are covered by Medicare and other government programs. Federal law has altered the payment rates available to providers of Medicare services in various ways during the last several years. Congress has passed legislation, which has reduced Medicare spending. It cannot yet be predicted how future changes in reimbursement levels will affect the home oxygen industry and there can be no assurance that such changes will not have an adverse effect on the Company’s business.
Patents and Trademarks
The Company pursues a policy of protecting its intellectual property rights including, obtaining patents for appropriate inventions related to products marketed or manufactured by the Company. The Company considers the patentability of its products to be significant to the success of the Company. To the extent that the products to be marketed by the Company do not receive patent protection, competitors may be able to manufacture and market substantially similar products. Such competition or claims that the Company’s products infringe the patent rights of others could have an adverse impact upon the Company’s business.
Product Liability
The nature of the Company’s business subjects it to potential legal actions asserting that the Company is liable for damages for product liability claims. Although the Company maintains product liability insurance in an amount which it believes to be customary in the industry, there is no assurance that this insurance will be sufficient to cover the costs of defense or judgments which might be entered against the Company. The type and frequency of these claims could have an adverse impact on the Company’s results of operations and financial position.
CHAD THERAPEUTICS, INC.
Management’s Discussion and Analysis of
Financial Condition and Results of Operations
December 31, 2001
Availability of Third Party Component Products
The Company tests and packages its products in its own facility. Some of its other manufacturing processes are conducted by other firms and the Company expects to continue using outside firms for certain manufacturing processes for the foreseeable future and is thus dependent on the reliability and quality of parts supplied by these firms. The Company’s agreements with its suppliers are terminable at will or by notice. The Company believes that other suppliers would be available in the event of termination of these arrangements. No assurance can be given, however, that the Company will not suffer a material disruption in the supply of its products.
Accounting Standards
Accounting standards promulgated by the Financial Accounting Standards Board change periodically. Changes in such standards may have an impact on the Company’s future financial position.
In July 2001, the Financial Accounting Standards Board issued FASB Statement No. 142, Accounting for Goodwill and Other Intangible Assets. Statement 142 will require that intangible assets with estimable useful lives be amortized over their respective useful lives to their estimated residual values and reviewed for impairment in accordance with FAS Statement No. 121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of. The Company is required to adopt the provisions of Statement 142 effective April 1, 2002. The adoption of Statement 142 is not expected to have a material impact on the financial statements of the Company.
In October 2001, the Financial Accounting Standards Board issued FASB Statement No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. While Statement No. 144 supersedes FASB Statement No. 121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of, it retains many of the fundamental provisions of that Statement. The Company is required to adopt the provisions of Statement 144 effective April 1, 2002. The adoption of Statement 144 is not expected to have a material impact on the financial statements of the Company.
Additional Risk Factors
The Company does not have any off balance sheet arrangements with any special purpose entities or any other parties, does not enter into any transactions in derivatives and has no material transactions with any related parties.
Additional factors, which might affect the Company’s performance, may be listed from time to time in the reports filed by the Company with the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CHAD THERAPEUTICS, INC. (Registrant) |
||||||
| Date 2/05/02 | /S/ Thomas E. Jones | |||||
| Thomas E. Jones Chief Executive Officer |
| Date 2/05/02 | /S/ Earl L. Yager | |||||
| Earl L. Yager Chief Operating Officer, Chief Financial Officer and Secretary |